Results 11 to 20 of about 23,497 (215)

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort. [PDF]

J Int AIDS Soc
ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Llenas-García J, Arcos Rueda MDM, Calderón Hernaiz R, Pedrero Tomé R, Bisbal Pardo O, Matarranz M, Torralba M, Galindo Puerto MJ, Rodríguez A, Peñaranda Vera M, Sanjoaquín Conde I, de la Fuente Moral S, Cabello-Úbeda A, Navarro San Francisco C, Antelo Cuéllar K, Pedrosa Aragón M, Aguilera García M, Tiraboschi J, Martínez Álvarez RM, Vivancos MJ, Montero Hernández C, Bernal Morell E, Cabello-Clotet N, Morano Amado LE, Gisbert Pérez L, Sepúlveda MA, Alemán Valls MR, Sánchez Guirao AJ, Fanciulli C, Escrig C, Ferreira Pasos EM, Lucas-Dato A, García Torras S, Hidalgo Tenorio C, Estébanez M, Muelas-Fernandez M, Losa García JE, Cerezales Calviño A, Pino Díaz ME, Martínez Montes C, Arenas García V, Arnaiz de Las Revillas F, Pernas Pardavila H, Padilla S, Garcinuño Jiménez MÁ, Alonso Alonso L, Ramos Vicente N, Barragán Gallo PN, Cabo Magadan R, Del Álamo M, Egido Murciano MV, Juárez Toquero A, Romero Palacios A, Clavero Olmos M, García Navarro MDM, Sanz J, Gainzarain JC, Milian Sanz M, de la Calle B, Ferrero Benéitez OL, Troya J, Buzón-Martín L, RELATIVITY Group.   +62 more
europepmc   +2 more sources

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

AIDS Research and Therapy, 2023
Background Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied.
Soo-Yon Rhee, Jonathan M. Schapiro, Francesco Saladini, Maurizio Zazzi, Saye Khoo, Robert W. Shafer   +5 more
doaj   +1 more source

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance. [PDF]

PLoS Pathogens, 2018
Reverse transcriptase (RT) is the target for the majority of anti-HIV-1 drugs. As with all anti-AIDS treatments, continued success of RT inhibitors is persistently disrupted by the occurrence of resistance mutations.
Meytal Galilee, Akram Alian
doaj   +1 more source

Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study. [PDF]

HIV Med
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Mussini C, Henegar C, Assoumou L, de Wit S, Johnson M, Quiros-Roldan E, Kenyon C, Deschanvres C, Zucman D, Post F, Movahedi R, Comi L, Fox J, Liegeon G, Martin C, Edwards J, Tiecco G, Delforge M, Ragone L, Jones B, van Wyk J, Aboud M, Fletcher C, Pozniak A, Vannappagari V.   +24 more
europepmc   +2 more sources

Genotype resistance profiles in patients failing an NNRTI‐containing regimen, and modifications after stopping NNRTI therapy [PDF]

Journal of Clinical Laboratory Analysis, 2002
AbstractResistance to non‐nucleoside reverse transcriptase inhibitors (NNRTIs) develops quickly and independently if they are used in combination with NRTIs or protease inhibitors (PIs) as rescue therapy, mainly due to the low genetic barrier of this class of drugs.
QUIROS ROLDAN, Maria Eugenia, Airoldi M, Moretti F, Fausti C, Pan A, CASARI, Salvatore, TORTI, Carlo, CASTELLI, Francesco, CAROSI, Giampiero   +8 more
openaire   +3 more sources

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.

PLoS Medicine, 2020
BackgroundRising resistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the success of the global scale-up of antiretroviral therapy (ART).
Anthony Hauser, Katharina Kusejko, Leigh F Johnson, Huldrych F Günthard, Julien Riou, Gilles Wandeler, Matthias Egger, Roger D Kouyos   +7 more
doaj   +1 more source

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

Журнал инфектологии, 2018
A randomized multicenter 96-week study of an elsulfavirine (ESV),  non-nucleoside reverse transcriptase inhibitor (NNRTI) of novel  generation, in combination with 2 nucleoside/ nucleotide reverse  transcriptase inhibitors (NRTIs) was conducted in naive ...
A. V. Kravchenko, E. A. Orlova-Morozova, T. E. Shimonova, O. A. Kozyrev, F. I. Nagimova, N. G. Zaharova, E. S. Ivanova, U. A. Kuimova, A. A. Popova, O. E. Chernova, O. S. Tonkih, D. A. Gusev, A. A. Yakovlev, V. V. Pokrovsky, V. V. Bychko, N. V. Vostokova   +15 more
doaj   +1 more source

Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. [PDF]

PLoS ONE, 2011
Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996-2006.Population costs for HIV services are increasing in the UK and interventions need to be effective ...
Eduard J Beck, Sundhiya Mandalia, Gary Lo, Peter Sharott, Mike Youle, Jane Anderson, Guy Baily, Ray Brettle, Martin Fisher, Mark Gompels, George Kinghorn, Margaret Johnson, Brendan McCarron, Anton Pozniak, Alan Tang, John Walsh, David White, Ian Williams, Brian Gazzard, NPMS-HHC Steering Group   +19 more
doaj   +1 more source

Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To assess the virological outcomes, prevalence of HIV drug resistance mutation (DRM), and correlates in Butuo County. Methods: We conducted a cross-sectional study.
Minghong Chen, Min Wu, Liyan Zeng, Yong Zhang, Muzuo Huobu-mo, Juhua Li, Chaoqun Li, Hong Xiao   +7 more
doaj   +1 more source